Will AIIM Replace Biotech Grant DAOs—or Work Alongside Them?

Getting your Trinity Audio player ready...

AI Internet-Meritocracy (AIIM) is unlikely to eliminate grant-based organizations such as VitaDAO. A more probable outcome is a hybrid scientific economy: specialized DAOs will finance uncertain, capital-intensive projects in advance, while AIIM will continuously reward researchers, software developers, reviewers, and other contributors according to demonstrated value.

AIIM may eventually allocate more total funding than individual biotech DAOs. However, even a mature AIIM system would not remove biotechnology’s need for laboratories, project management, regulatory oversight, intellectual-property structures, and substantial financing before results exist.

The two models solve different problems.

Grant DAOs and AIIM Fund Different Units of Science

A conventional grant-based DAO asks:

Which proposed project should receive money before the work is completed?

AIIM asks a different question:

Which existing scientific and technical contributions appear most valuable, and how should available money be distributed among their contributors?

This distinction is fundamental.

Organizations such as VitaDAO concentrate resources on defined research programs. VitaDAO describes itself as a community-owned collective funding and advancing early-stage longevity science. Token holders participate in funding proposals and treasury governance.

By contrast, AI Internet-Meritocracy is intended to evaluate scientific and open-source contributions across the Internet and distribute donations according to measurable merit, usefulness, and impact. It is therefore closer to a continuous, automated prize system than to a conventional proposal-based grant committee.

Model	Primary object funded	Timing	Main selection mechanism
Traditional grant DAO	A proposed project	Before or during research	Community and expert evaluation
AIIM	Contributions and contributors	Primarily after observable work	AI-assisted merit and impact assessment
Hybrid model	Projects plus demonstrated contributions	Before, during, and after research	Grants, milestones, AI evaluation, and governance

VitaDAO Is Specialized by Design

VitaDAO’s concentration on longevity biotechnology is not merely an arbitrary limitation. Specialization creates capabilities that a universal funding algorithm may not initially possess.

Biotechnology projects frequently require:

• laboratory facilities and physical materials;
• ethical and biosafety review;
• experimental protocols;
• milestone supervision;
• specialist scientific judgment;
• intellectual-property management;
• regulatory planning;
• coordination among researchers, laboratories, manufacturers, and investors.

VitaDAO is not simply distributing charitable donations among scientists. It participates in a broader system of community-governed drug development and research commercialization. Its official GitHub description characterizes it as a cooperative vehicle for decentralized drug development.

This specialization gives biotech DAOs an advantage when funding a particular molecule, experiment, therapeutic hypothesis, or development program.

LabDAO Is Not Merely Another Grant DAO

LabDAO should be distinguished from VitaDAO.

Its original emphasis was not simply selecting projects and awarding grants. It sought to create an open network through which scientists could access computational tools, laboratory services, collaboration, and research infrastructure. Contemporary descriptions characterize it as an execution layer or peer-to-peer research network, particularly for computational life science and open drug discovery.

This makes LabDAO conceptually relevant to AIIM in another way: AIIM could reward the people who build and maintain shared scientific infrastructure, while a network such as LabDAO could provide the infrastructure through which research is performed.

For example:

1. A biotech DAO finances a protein-design project.
2. Researchers use open computational services or laboratory infrastructure.
3. Developers improve the software used by the project.
4. Independent reviewers examine the resulting data.
5. AIIM evaluates the visible contributions and distributes additional funding among the researchers, developers, data curators, and reviewers.

The systems would be complementary rather than redundant.

Why AIIM Can Cover More Fields Than Existing DeSci DAOs

Most current DeSci organizations are organized around a field, disease, technology, or community. Biotechnology has attracted particular attention because it offers identifiable projects, potential patents, commercial products, and narratives that donors and token holders can readily understand.

Pure mathematics is much harder to finance through the same structure.

A mathematical contribution may:

• have no patentable output;
• require no formal laboratory;
• remain useful for centuries;
• support many unrelated fields;
• be produced by one independent researcher;
• become important only after later work depends on it.

Creating a separate DAO for every branch of mathematics, theoretical physics, computer science, linguistics, or philosophy of science would be inefficient. Small fields might never attract enough participants to maintain their own treasuries, governance processes, and expert-review systems.

AIIM’s proposed advantage is domain breadth. It is intended to compare and support contributions across science and free and open-source software rather than requiring every discipline to build a separate funding institution.

This could make AIIM particularly important for:

• abstract and foundational mathematics;
• theoretical research without immediate commercialization;
• scientific software and digital infrastructure;
• replication and negative results;
• data maintenance;
• informal peer review;
• independent researchers;
• interdisciplinary work that does not fit one specialized DAO.

The AIIM non-discriminatory funding model is explicitly designed to shift attention from institutional status and proposal-writing ability toward observable intellectual contribution.

Could AIIM Eventually Become Larger Than Biotech DAOs?

Yes. AIIM could eventually distribute more money than specialized DAOs, including within biotechnology.

A universal allocation layer has several potential scaling advantages.

A Larger Contributor Base

A longevity DAO serves a specific research community. AIIM could potentially include mathematicians, biologists, physicists, programmers, reviewers, educators, and infrastructure maintainers within the same funding network.

Lower Marginal Evaluation Costs

Grant review is labor-intensive. Every proposal must be submitted, assigned, read, discussed, approved, and monitored.

An automated system could continuously process public evidence such as:

• papers and preprints;
• software repositories;
• datasets;
• documented dependencies;
• independent evaluations;
• replications;
• citations and downstream applications;
• corrections and peer-review activity.

Human supervision would still be required, but automation could reduce the cost of allocating many small payments.

Support for Contributions Too Small for a Grant

Not every valuable contribution is a complete research project. A corrected proof, maintained dependency, improved dataset, unsuccessful replication, or detailed review may be extremely useful without justifying a conventional grant application.

AIIM could make such work economically visible.

Cross-Disciplinary Dependency Analysis

Biotechnology depends on work outside biology: statistics, optimization, database systems, machine learning, laboratory software, mathematical modeling, and scientific standards.

A universal system could trace these relationships more effectively than a DAO whose mandate stops at the boundary of one discipline.

Why AIIM Will Not Completely Replace Ex-Ante Grants

A system that rewards completed contributions faces an unavoidable limitation: some research cannot begin without advance financing.

A mathematician may need primarily time and access to information. A biotechnology team may need equipment, reagents, laboratory personnel, animal studies, manufacturing capacity, or clinical infrastructure before it can produce any publicly assessable result.

This creates a financing gap:

Retroactive rewards can compensate successful work, but they cannot purchase every prerequisite needed to start that work.

Scientific-grant economics therefore distinguishes grants from prizes and patents. Grants are especially relevant where research is uncertain, costly, and impossible to finance solely from expected future rewards. Research on grant design also emphasizes staged financing and monitoring as mechanisms for dealing with uncertainty and researcher incentives.

Consequently, AIIM should not be designed as a dogmatic prohibition against grants. It should be understood as an additional allocation layer that corrects weaknesses in proposal-centered funding.

The Most Likely Outcome: A Hybrid Funding Stack

The strongest architecture would combine several mechanisms.

1. Specialized DAOs Supply Project Capital

VitaDAO and comparable organizations can identify promising biotech programs, assemble expert communities, manage IP, and provide money before results are available.

2. Milestone Systems Control Risk

Large projects can receive funding in stages rather than through a single unconditional transfer. Experimental progress, data release, protocol completion, or independent validation can unlock subsequent tranches.

3. AIIM Rewards Demonstrated Contribution

AIIM can distribute continuous funding according to work that has become visible and assessable. This may include contributions that the original project budget overlooked.

4. Human Governance Handles Exceptional Cases

AI models can make systematic assessments, but humans must remain responsible for defining legitimate evidence, resolving disputes, addressing manipulation, and changing the rules when the system produces unacceptable outcomes.

5. Open Infrastructure Connects the Layers

Blockchains, non-custodial treasuries, public records, reproducible software, and transparent evaluation data can connect project funding with later impact assessment.

Under this design, AIIM would not compete with every DAO for the same institutional role. It would become a shared merit-allocation infrastructure used by many DAOs.

How AIIM Could Operate Inside Biotechnology

Suppose a longevity DAO awards $500,000 to investigate a new therapeutic target.

The DAO must evaluate the proposal, contract with laboratories, establish milestones, and supervise the project. AIIM does not remove these responsibilities.

However, AIIM could later evaluate:

• the researchers who designed the study;
• the laboratory that produced reliable data;
• developers of software used in the analysis;
• authors of earlier work on which the hypothesis depended;
• scientists who reproduced or challenged the findings;
• reviewers who identified methodological errors;
• data curators who made the results reusable;
• open-source maintainers whose work supported the experiment.

The grant pays for the project. AIIM pays for the wider network of contribution.

This is particularly important because the legal recipient of a grant is not always identical to the set of people who created the project’s scientific value.

AIIM May Put Competitive Pressure on Grant DAOs

Coexistence does not mean that nothing will change.

AIIM could expose weaknesses in grant-based DAOs when:

• funding repeatedly follows popularity rather than evidence;
• token ownership substitutes for scientific competence;
• insiders dominate proposal selection;
• excessive funding goes to presentation and marketing;
• unsuccessful but informative results receive no recognition;
• software and foundational dependencies remain unpaid;
• researchers outside established networks cannot obtain consideration.

If AIIM demonstrates that it can identify valuable contributors more accurately and cheaply, donors may redirect part of their money from discretionary grant pools toward automated distribution.

Specialized DAOs would then have to justify their additional administrative costs by providing services that AIIM cannot provide: advance capital, scientific coordination, laboratory access, legal structures, commercialization, and concentrated strategic direction.

That would be healthy competition.

AIIM Must First Prove Its Own Claims

AIIM’s breadth is currently an ambition, not a demonstrated guarantee of superior allocation.

A universal scientific evaluator faces difficult problems:

• comparing contributions across incomparable disciplines;
• distinguishing genuine influence from citation popularity;
• detecting coordinated manipulation;
• evaluating confidential or proprietary work;
• assessing negative results;
• allocating credit among collaborators;
• recognizing contributions before a consensus forms;
• avoiding systematic bias toward work with abundant digital evidence;
• judging long-term foundational value from short-term signals.

Biotechnology creates additional difficulties because important evidence may be private, regulated, commercially sensitive, or impossible for a general AI model to verify directly.

AIIM therefore needs auditable criteria, transparent uncertainty estimates, appeal procedures, adversarial testing, and strong governance. It should not claim that algorithmic evaluation automatically produces justice. Its legitimacy must come from verifiable design and performance.

Will AIIM Overcome Grant Funding in Biotech?

The answer depends on what “overcome” means.

AIIM may overcome grant DAOs in the volume and breadth of routine merit-based payments. It could become the principal mechanism for rewarding the distributed network of people and software behind biotechnology.

AIIM is less likely to eliminate project grants. Wet-lab science requires advance commitments, physical resources, concentrated management, and acceptance of substantial failure risk.

AIIM could eventually become the allocation layer above grant DAOs. Donors might contribute to a universal AIIM pool, specialized DAOs might use AIIM scores when selecting projects, and successful project participants might receive additional retroactive funding through AIIM.

The future is therefore unlikely to be “VitaDAO versus AIIM.” A more realistic structure is:

Grant DAOs finance scientific bets. AIIM evaluates the resulting ecosystem of contributions.

Conclusion

Specialized DeSci organizations and AIIM address different stages of scientific production.

VitaDAO can concentrate capital, expertise, and governance around longevity research. Laboratory and computational networks can provide tools for conducting that research. AIIM can evaluate contributions across organizational and disciplinary boundaries and direct funding toward people whose work proves useful.

In fields such as pure mathematics and foundational science, AIIM may become more important than project-specific DAOs because there is often no laboratory, patent portfolio, or commercial product around which to organize a conventional funding community.

In biotechnology, however, the likely winner is not one model but a layered system:

• grants for starting expensive and uncertain projects;
• milestone financing for controlling execution risk;
• AIIM payments for demonstrated contribution and downstream impact;
• human governance for appeals, safety, and exceptional decisions.

AIIM could become broader than the existing DeSci sector without making specialized DAOs obsolete. Its strongest role may be to connect them, evaluate what they miss, and ensure that scientific value is rewarded beyond the boundaries of individual projects.